Sagimet Biosciences (SGMT) Income from Continuing Operations (2022 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Income from Continuing Operations of 13818000.0 for Q1 2026, up 30.91% year-over-year from 10555343.37 in Q1 2025, and down 3.37% quarter-over-quarter from 13367000.0 in Q4 2025.
Sagimet Biosciences (SGMT) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 13818000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 30.91% year-over-year to 13818000.0; the TTM figure through Mar 2026 stood at 69877000.0 (up 46.13% YoY), while the FY2025 annual figure was 54837000.0, up 51.02% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 13818000.0, down from 13367000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 6694000.0 in Q1 2023, with the low at 82592000.0 in Q4 2024.
- The 5-year median for Income from Continuing Operations is 15128000.0 (2024), against an average of 21766937.5.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations tumbled 657.31% in 2024, then surged 83.82% in 2025.
- Sagimet Biosciences' Income from Continuing Operations stood at 55029000.0 in 2022, then soared by 80.18% to 10906000.0 in 2023, then sank by 657.31% to 82592000.0 in 2024, then soared by 83.82% to 13367000.0 in 2025, then declined by 3.37% to 13818000.0 in 2026.
- Business Quant data shows SGMT's Income from Continuing Operations at 13818000.0 in Q1 2026, 13367000.0 in Q4 2025, and 19956000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - | -27.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.88 Mn |
| Mar 31, 2026 | -13.82 Mn |
| Dec 31, 2025 | -13.37 Mn |
| Sep 30, 2025 | -19.96 Mn |
| Jun 30, 2025 | -22.74 Mn |
| Mar 31, 2025 | -20.00 Mn |
| Dec 31, 2024 | -82.59 Mn |
| Sep 30, 2024 | -16.44 Mn |
| Jun 30, 2024 | -10.67 Mn |
| Mar 31, 2024 | -8.80 Mn |
| Dec 31, 2023 | -10.91 Mn |
| Sep 30, 2023 | -24.09 Mn |
| Jun 30, 2023 | -28.36 Mn |
| Mar 31, 2023 | -6.69 Mn |
| Dec 31, 2022 | -55.03 Mn |
| Sep 30, 2022 | -7.47 Mn |
| Jun 30, 2022 | -7.34 Mn |